Hemophilia Gene Therapy Pipeline — PatSnap Eureka
Hemophilia A & B Gene Therapy Pipeline: AAV Factor Replacement
From BDD-FVIII codon optimization to chimeric AAV capsids and non-viral platforms — explore the patent and clinical signals shaping the hemophilia gene therapy landscape, powered by PatSnap Eureka.
F8 and F9: The Central Genetic Targets in Hemophilia Gene Therapy
Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency) are X-linked inherited bleeding disorders representing among the most clinically and commercially significant targets in gene therapy for rare diseases. Retrieved results uniformly identify the F8 gene (encoding coagulation Factor VIII, FVIII) and the F9 gene (encoding coagulation Factor IX, FIX) as the primary molecular targets for hemophilia A and B gene therapy, respectively.
A critical challenge highlighted across multiple retrieved patents is the size of the FVIII coding sequence. The full-length wild-type FVIII polypeptide (2,351 amino acids; UniProt P00451) is five times larger than wild-type FIX (461 amino acids; UniProt P00740), and its coding sequence of approximately 7,053 base pairs exceeds the packaging capacity of conventional AAV vectors. Takeda Pharmaceutical Company and Baxalta Incorporated identify this as the central engineering constraint driving adoption of B-domain deleted (BDD) FVIII constructs and codon optimization strategies.
Elevating clotting factor activity to as little as 1% above normal is sufficient to significantly reduce spontaneous bleeding events and long-term joint pathology. The liver is identified across retrieved results as the primary physiological site of FIX and FVIII synthesis and the preferred target organ for gene delivery — both for efficient entry of secreted factors into circulation and for induction of regulatory T cell (Treg)-mediated immune tolerance to transgene products. For further context on coagulation factor biology, see resources from the National Institutes of Health and the World Federation of Hemophilia.
A secondary molecular challenge involves inhibitor antibody formation: 15–30% of individuals receiving FVIII replacement therapy develop neutralizing anti-FVIII antibodies, complicating both protein replacement and gene therapy approaches. Approximately 10% of hemophilia B patients similarly develop anti-FIX inhibitors.
Six Distinct Approaches Across the Hemophilia Gene Therapy Pipeline
From liver-directed AAV delivery to non-viral platforms and genomic integration, patent and literature records reveal a multi-modal innovation landscape.
AAV Liver-Directed Gene Therapy (FVIII)
The dominant modality in retrieved results. Recombinant AAV delivery of engineered BDD-FVIII transgenes to hepatocytes via AAV5, AAV6, AAV8, and chimeric capsids. Valoctocogene roxaparvovec (BioMarin) has received European Commission approval; 134 patients enrolled in Phase 3. Clinical programs also include SPK-8011 (Spark Therapeutics, 18 patients) and giroctocogene fitelparvovec (Pfizer/Sangamo, 11 patients).
Phase 3 / Approved (EU)AAV Liver-Directed Gene Therapy (FIX)
A well-established paradigm that preceded hemophilia A efforts. Stanford University's filing describes a chimeric AAV capsid encoding a modified FIX polypeptide with enhanced potency, enabling lower doses. Regeneron's patent covers F9 insertion at the endogenous albumin (ALB) genomic locus — a stable integration strategy distinct from episomal AAV. The first AAV2-mediated FIX gene transfer to human liver was reported by Manno et al. (2006).
Phase 2/3 Advanced ClinicalCodon Optimization & FVIII Variant Engineering
Systematic codon alteration of FVIII polynucleotides from Takeda, Baxalta, and Spark Therapeutics. Strategies include elimination of CpG dinucleotides (reducing innate immune activation), amino acid substitutions to improve secretion efficiency (e.g., F328S), and heterologous signal peptides to enhance ER entry. The CS04 codon-optimized construct was tested in at least four hemophilia A patients via rAAV8 per retrieved patent data.
Preclinical / IND-EnablingChimeric Protein & Extended Half-Life Factor Replacement
Bioverativ Therapeutics (now Sanofi) and Biogen MA describe chimeric FVIII/FIX polypeptides fused to Fc domains, von Willebrand factor (VWF) fragments, and/or XTEN polypeptide sequences to extend half-life and reduce dosing frequency. VWF D' and D3 domains are used as fusion partners, exploiting the natural VWF-FVIII interaction. rFVIIIFc (efmoroctocog alfa) is referenced in prescribing information in retrieved records, suggesting approved or advanced-stage status.
Clinical / ApprovedNon-Viral & Alternative Delivery Platforms
Generation Bio Co.'s 2023 patent describes closed-end DNA (ceDNA) vectors — non-viral, capsid-free, linear DNA constructs flanked by inverted terminal repeats — for FVIII expression. This filing explicitly highlights AAV limitations: pre-existing immunity in 25–40% of patients, inability to redose, and uncontrollable dose levels as motivating factors. Genzyme (Sanofi) describes lipid nanoparticle (LNP) delivery targeting hematopoietic stem cells (HSC) as an emerging alternative platform.
Preclinical / Early DevelopmentGene Editing / F8 Mutation Repair
Records from the U.S. Government, the Regents of the University of California, and Haplomics, Inc. describe F8 gene repair using AAV vectors delivering donor templates, combined with immune tolerance induction to the subsequently expressed FVIII protein. This strategy is distinct from transgene addition and represents a precision correction approach addressing both the genetic deficit and inhibitor antibody barriers simultaneously.
Early PreclinicalKey Quantitative Signals from Patent & Literature Records
Data extracted from retrieved patent records and academic literature. All values are traceable to source documents in this dataset.
Hemophilia Gene Therapy: Modality Development Stage Distribution
Distribution of six identified therapeutic modalities across development stages, from approved products to early preclinical programs.
AAV Serotypes in Hemophilia A Gene Therapy Programs
Dosing ranges (vg/kg) across three clinical-stage AAV serotypes as reported in University Medical Centre Utrecht 2022 paper.
Inhibitor Antibody Formation Rates in Hemophilia Treatment
Percentage of patients developing neutralizing inhibitor antibodies — a key barrier for both protein replacement and gene therapy approaches.
Key Assignee Activity: Patent Jurisdiction Reach
Number of jurisdictions with active/pending patent filings per major assignee in this dataset, signaling commercial IP prioritisation.
Who Controls the Hemophilia Gene Therapy Patent Space?
Retrieved results are heavily patent-driven. The following organizations are represented across multiple jurisdictions in this dataset.
Track Competitor IP Activity in Real Time
Monitor new hemophilia gene therapy patent filings across all jurisdictions with PatSnap IP Analytics.
Key Strategic Implications from Patent & Literature Analysis
Derived exclusively from retrieved patent records and academic literature in this dataset.
Crowded IP Space: BDD-FVIII & Codon Optimization
Codon optimization and BDD-FVIII engineering represent a crowded IP space dominated by Takeda/Baxalta, Spark Therapeutics, BioMarin, and UNC Chapel Hill, with overlapping claims across multiple jurisdictions. New entrants pursuing AAV/FVIII gene therapy will face significant freedom-to-operate challenges and should evaluate differentiation through novel capsids, novel regulatory elements, or non-AAV platforms.
Durability: The Central Unresolved Clinical Issue
Retrieved academic literature explicitly frames long-term follow-up data as the key uncertainty in hemophilia A gene therapy. BioMarin IP addresses the adolescent patient population where episomal AAV vector genome dilution during liver growth is expected to limit durability — indicating the field will need genomic integration or redosing solutions to achieve sustained therapeutic benefit.
Combination Approaches & Next-Generation Strategies
Six emerging combination strategies and platform innovations signaled by retrieved patent records, spanning pharmacological augmentation to genomic integration.
Proteasome Inhibitor + AAV (Enhanced Transduction)
Retrieved patents from the University of North Carolina at Chapel Hill describe co-administration of bortezomib (Velcade) with AAV vectors containing oversized genomes as a strategy to enhance parvoviral transduction efficiency in hemophilia A — a preclinical combination approach signaling interest in pharmacological augmentation of gene delivery.
PreclinicalImmune Tolerance Induction + FVIII Gene Repair
Records from the U.S. Government and Haplomics, Inc. describe combining F8 gene repair (via AAV-delivered donor templates) with induction of immune tolerance to the resultant repaired FVIII protein — a dual-mechanism approach addressing both the genetic deficit and inhibitor antibody barriers simultaneously.
Early PreclinicalFVIII-Fc-XTEN-VWF Triple Half-Life Extension
Retrieved Bioverativ/Biogen patents describe FVIII-Fc-XTEN-VWF fusion constructs combining multiple half-life extension strategies: Fc recycling, steric XTEN shielding, and VWF stabilization. Signals suggest this modality remains active and evolving toward longer dosing intervals, with relevance to life sciences IP strategy.
Clinical / EvolvingLNP + HSC-Targeted Non-AAV Delivery
The Genzyme (Sanofi) patent from 2026 (filing date) on HSC-specific antibody-conjugated lipid nanoparticles for F8/F9 transgene delivery signals an emerging non-AAV gene delivery approach that would permit repeat dosing and avoid anti-AAV immunity — a direction actively being explored to overcome core AAV limitations and serve the 25–40% of patients currently excluded.
Early DevelopmentGenomic Integration at ALB Locus (Hemophilia B)
Regeneron's patent on FIX insertion at the albumin genomic locus signals interest in stable, integration-based approaches that persist through cell division — potentially addressing the durability concerns of episomal AAV in dividing hepatocytes, particularly relevant for pediatric patients where liver growth causes vector genome dilution.
PreclinicalTreating Anti-AAV Seropositive Patients
BioMarin's 2024 WO patent specifically covers methods for treating AAV-seropositive patients and enabling re-dosing, signaling recognition that ~25–40% of patients are excluded from first-generation AAV gene therapies. IP protection of solutions to this barrier is commercially strategic, as confirmed by this filing. Regulatory guidance from EMA and FDA continues to evolve on this challenge.
Commercial IP PriorityHemophilia Gene Therapy Pipeline — key questions answered
The F8 gene (encoding coagulation Factor VIII, FVIII) and the F9 gene (encoding coagulation Factor IX, FIX) are the primary molecular targets for hemophilia A and B gene therapy, respectively. Hemophilia A is the most common inherited bleeding disorder, occurring in approximately 1 in 5,000 live male births in the United States, with hemophilia A being approximately four times more prevalent than hemophilia B.
The full-length wild-type FVIII polypeptide (2,351 amino acids) is five times larger than wild-type FIX (461 amino acids), and its coding sequence of approximately 7,053 base pairs exceeds the packaging capacity of conventional AAV vectors. This drives adoption of B-domain deleted (BDD) FVIII constructs and codon optimization strategies.
A 2022 academic paper from the University Medical Centre Utrecht describes four active clinical trials: valoctocogene roxaparvovec (AAV5-hFVIII-SQ; BioMarin) with 134 patients enrolled in phase 3; SPK-8011 (AAV3-based; Spark Therapeutics) with 18 patients; and giroctocogene fitelparvovec (AAV6-hFVIII-SQ; Pfizer/Sangamo) with 11 patients. Valoctocogene roxaparvovec (ROCTAVIAN) has received European Commission approval per BioMarin patent records.
A gain-of-function FIX variant (FIX-Padua/Ile338Leu or FIX-Triple) is referenced in Vrije Universiteit Brussel patents as improving hemostasis efficacy without increased thrombosis risk in mouse models, enabling dose reduction of the AAV vector. Retrieved Stanford patent signals that combining improved hepatotropic capsids with high-potency FIX variants can substantially lower therapeutic vector dose, which has favorable safety, manufacturing cost, and dose-titration implications.
Key limitations include: pre-existing anti-AAV immunity excluding 25–40% of patients from treatment; inability to redose following seroconversion; episomal AAV vector genome dilution during liver growth in adolescent patients limiting durability; and inhibitor antibody formation (15–30% of FVIII replacement therapy patients develop neutralizing anti-FVIII antibodies).
A 2023 patent from Generation Bio Co. describes closed-end DNA (ceDNA) vectors — non-viral, capsid-free, linear DNA constructs flanked by inverted terminal repeats — for FVIII expression in hemophilia A. Retrieved records from Genzyme (Sanofi) describe lipid nanoparticle (LNP) delivery of gene payloads targeting hematopoietic stem cells (HSC) as a platform for hemophilia. These represent emerging alternatives to AAV-based approaches.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka DirectlyAccelerate Your Hemophilia Gene Therapy Research
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from AAV capsid freedom-to-operate to clinical pipeline intelligence.
References
- A Cure For Hemophilia: the Promise Becomes a Reality — Anonymous/Review, 2016
- Gene Therapy for Hemophilia A: How Long Will It Last? — University Medical Centre Utrecht, 2022
- Optimized human clotting Factor VIII gene expression cassettes and their use — University of North Carolina at Chapel Hill, 2020 [AU Patent]
- Chimeric factor VIII polypeptides and uses thereof — Biogen MA Inc., 2016 [AU Patent]
- Factor VIII (FVIII) Gene Therapy — Spark Therapeutics, Inc., 2024 [JP Patent]
- Methods of treating Anti-AAV seropositive hemophilia patients — BioMarin Pharmaceutical Inc., 2024 [WO Patent]
- Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression — Takeda Pharmaceutical Company Limited, 2024 [US Patent]
- Vector for liver-directed gene therapy of hemophilia and methods and use thereof — Vrije Universiteit Brussel, 2019 [US Patent]
- Gene therapy for hemophilia B with a chimeric AAV capsid vector encoding modified Factor IX polypeptides — Stanford University, 2021 [WO Patent]
- Compositions and methods for expressing Factor IX for hemophilia B therapy — Regeneron Pharmaceuticals, Inc., 2024 [JP Patent]
- Non-viral DNA vectors and uses thereof for expressing FVIII therapeutics — Generation Bio Co., 2023 [CN Patent]
- National Institutes of Health — Hemophilia research and coagulation factor biology resources
- World Federation of Hemophilia — Global hemophilia disease burden and treatment guidelines
- European Medicines Agency — Gene therapy regulatory guidance and approved product information
- U.S. Food and Drug Administration — Gene therapy guidance documents and clinical trial information
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.